Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19
Publication
, Journal Article
Reyno, L; Seymour, L; Tu, D; Dent, S; Gelmon, K; Walley, B; Pluzanska, A; Gorbunova, V; Garin, A; Jassem, J; Pienkowski, T; Dancey, J; Voi, M ...
Published in: Women's Oncology Review
June 1, 2004
Duke Scholars
Published In
Women's Oncology Review
DOI
ISSN
1473-3404
Publication Date
June 1, 2004
Volume
4
Issue
2
Start / End Page
133 / 134
Citation
APA
Chicago
ICMJE
MLA
NLM
Reyno, L., Seymour, L., Tu, D., Dent, S., Gelmon, K., Walley, B., … Rutovitz, J. J. (2004). Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19. Women’s Oncology Review, 4(2), 133–134. https://doi.org/10.1080/14733400410001728456
Reyno, L., L. Seymour, D. Tu, S. Dent, K. Gelmon, B. Walley, A. Pluzanska, et al. “Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19.” Women’s Oncology Review 4, no. 2 (June 1, 2004): 133–34. https://doi.org/10.1080/14733400410001728456.
Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, et al. Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19. Women’s Oncology Review. 2004 Jun 1;4(2):133–4.
Reyno, L., et al. “Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19.” Women’s Oncology Review, vol. 4, no. 2, June 2004, pp. 133–34. Scopus, doi:10.1080/14733400410001728456.
Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K, Marx GM, Rutovitz JJ. Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19. Women’s Oncology Review. 2004 Jun 1;4(2):133–134.
Published In
Women's Oncology Review
DOI
ISSN
1473-3404
Publication Date
June 1, 2004
Volume
4
Issue
2
Start / End Page
133 / 134